GASTRIC-MUCOSAL PROTECTION BY YM638, A NOVEL LEUKOTRIENE D-4 RECEPTOR ANTAGONIST, IN RATS

被引:2
|
作者
MIYATA, K
KAMATO, T
NISHIDA, A
TAKIZAWA, K
TAKEDA, M
机构
[1] Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co. Ltd., Tsukuba, Ibaraki, 305
关键词
YM638 ([[5-[[3-(4-ACETYL-3-HYDROXY-2-PROPYLPHENOXY)PROPYL]THIO]-1,3,4-THIADIAZOL-2-YL]THIO] ACETIC ACID); LEUKOTRIENE D-4 RECEPTOR ANTAGONIST; GASTRIC MUCOSAL PROTECTION; GASTRIC LESION;
D O I
10.1016/0014-2999(95)00035-J
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
YM638 ([[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio] acetic acid) is a novel leukotriene D-4 receptor antagonist. We investigated the involvement of the leukotriene D-4 receptor blocking activity of YM638 in the gastric mucosal protection of this drug in rats. YM638 significantly prevented gastric lesion formation induced by water-immersion restraint stress, indomethacin, absolute ethanol, 0.7 N HCl and the combination of 0.2 N HCl and hemorrhagic shock, with ED(50) values of 26.4, 4.1, 4.7, 35.4 and 8.0 mg/kg p.o., respectively. Cetraxate and sofalcone showed inhibitory effects on most of these gastric lesions, but the inhibitory effects of these compounds were much weaker than those of YM638. In contrast, YM638 had no effect on gastric acid secretion and gastric lesion formation in pylorus-ligated rats, or on duodenal lesion formation in cysteamine-administered rats. YM638 competitively antagonized leukotriene D-4-induced contraction of the isolated stomach, with a pA(2) value of 7.63 +/- 0.18. In anesthetized rats, intravenous YM638 inhibited leukotriene D-4-induced aggravation of gastric lesions caused by HCl, and leukotriene D-4 and HCl-induced reduction of the potential difference. In addition, oral YM638 significantly increased gastric mucosal blood flow and prevented ethanol-induced increase in gastric vascular permeability. Endogenous prostaglandins, sulfhydryls and nitric oxides were not involved in this inhibitory effect on absolute ethanol-induced gastric lesion, YM638 did not react with the stable free radical 1,1-diphenyl-2-picrylhydrazyl in vitro, indicating that YM638 does not have potential as free radical scavenger. These results suggest that the preventive effect of YM638 on gastric lesions is attributable not only to its leukotriene D-4 receptor blocking activity but also to the activation of gastric mucosal defensive mechanisms such as mucosal blood flow and vascular permeability.
引用
收藏
页码:165 / 175
页数:11
相关论文
共 47 条
  • [41] Lafutidine, a novel H2 receptor antagonist, reduces the stress-induced gastric mucosal injury by inhibiting neutrophil activation through activation of capsaicin sensitive nerve in rats.
    Harada, N
    Okajima, K
    Uchiba, M
    GASTROENTEROLOGY, 2001, 120 (05) : A148 - A148
  • [42] Effects of NRA0045, a novel potent antagonist at dopamine D4, 5-HT2A, and α1 adrenaline receptors, and NRA0160, a selective D4 receptor antagonist, on phencyclidine-induced behavior and glutamate release in rats
    Abekawa, T
    Honda, M
    Ito, K
    Koyama, T
    PSYCHOPHARMACOLOGY, 2003, 169 (3-4) : 247 - 256
  • [43] Effects of NRA0045, a novel potent antagonist at dopamine D4, 5-HT2A, and α1 adrenaline receptors, and NRA0160, a selective D4 receptor antagonist, on phencyclidine-induced behavior and glutamate release in rats
    T. Abekawa
    M. Honda
    K. Ito
    T. Koyama
    Psychopharmacology, 2003, 169 : 247 - 256
  • [44] DESIGN AND SYNTHESIS OF SODIUM (BETA-R-STAR,GAMMA-S-STAR)-4-[[3-(4-ACETYL-3-HYDROXY-2-PROPYLPHENOXY)PROPYL]THIO]-GAMMA-HYDROXY-BETA-METHYLBENZENEBUTANOATE - A NOVEL, SELECTIVE, AND ORALLY ACTIVE RECEPTOR ANTAGONIST OF LEUKOTRIENE-D4
    YOUNG, RN
    BELANGER, P
    CHAMPION, E
    DEHAVEN, RN
    DENIS, D
    FORDHUTCHINSON, AW
    FORTIN, R
    FRENETTE, R
    GAUTHIER, JY
    GILLARD, J
    GUINDON, Y
    JONES, TR
    KAKUSHIMA, M
    MASSON, P
    MAYCOCK, A
    MCFARLANE, CS
    PIECHUTA, H
    PONG, SS
    ROKACH, J
    WILLIAMS, HWR
    YOAKIM, C
    ZAMBONI, R
    JOURNAL OF MEDICINAL CHEMISTRY, 1986, 29 (09) : 1573 - 1576
  • [45] Effect of the histamine H-2-receptor antagonist (+/-)-(E)-1-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-3'-[2-[[[5-(methylamino)methyl-2-furyl]methyl]thio]ethyl]-2''-(methylsulfonyl)guanidine on acute gastric mucosal injury in rats and its free-radical scavenging activities
    Naito, Y
    Yoshikawa, T
    Matsuyama, K
    Yagi, N
    Nakamura, Y
    Nishimura, S
    Kaneko, T
    Yoshida, N
    Kondo, M
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1997, 47 (07): : 845 - 848
  • [46] Effects of the novel histamine H-2-receptor antagonist (+/-)-(E)-1-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-3-[2-[[[5-(methylamino)methyl-2-furyl]methyl]thio]ethyl]-2-(methylsulfonyl)guanidine on gastric secretion and gastroduodenal ulcers in rats
    Amagase, K
    Kato, S
    Yamamoto, H
    Okabe, S
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1996, 46 (02): : 177 - 184
  • [47] The effect of subchronic administration of 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methylcyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526), a novel acid pump antagonist, on gastric acid secretion and gastrin levels in rats
    Ito, Keiichi
    Kinoshita, Kazuya
    Tomizawa, Atsuyuki
    Morikawa-Inomata, Yuka
    Inaba, Fumi
    Fujita, Yoshifumi
    Tabata, Keiichi
    Shibakawa, Nobuhiko
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 326 (01): : 163 - 170